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ABSTRACT
Objective: The  present  study  developed  and  validated a high-performance  liquid  chromatography-tandem  mass  spectrometry method  for 
simultaneous determination of vildagliptin, metformin, and metformin-related compounds (A, B, and C) in tablets.
Methods: Chromatographic separations were achieved on a C8 column (150 × 4.6 mm, 5 µm particle size) maintained at 25°C. The isocratic mobile 
phase consisted of acetonitrile/water/formic acid (20:80:0.1, v/v/v), eluted at 800 μL/min. The volume of injection was 20 μL and the electrospray 
source was operated in positive ion mode.
Results: Data from validation studies demonstrated that the new method was highly selective, sensitive (limits of detection ≤ 0.6 ng/mL), precise
(RSD < 5%), and accurate (RE < 5%). All of the calibration curves showed excellent coefficients of correlation (r ≥ 0.99) over the ranges of 5-150
ng/mL for vildagliptin, 250-2000 ng/mL for metformin, and 2.5-25 ng/mL for metformin-related compounds A, B, and C. Quantification of these 
compounds in tablets showed that they contained from 95.2-101.2% (vildagliptin) and 97-104.4% (metformin) of the stated level. No metformin-
related compounds were detected using this highly sensitive method.
Conclusion: This new  method  is  presented  as  an  alternative approach  to the  quality  control  of  tablets  containing vildagliptin,  metformin, and
metformin-related compounds.
Keywords: Diabetes, HPLC-MS/MS, Metformin, Metformin-related compound, Tablets, Vildagliptin. 
 
INTRODUCTION 
Failures of the secretion and/or activity of insulin causes a group of 
metabolic diseases named diabetes mellitus (DM). By 2030, more 
than 300 million people worldwide are expected to be diabetic and 
90-95% of these individuals will have type 2 DM (T2DM) [1, 2].  
Treatment of T2DM begins with lifestyle modification and 
pharmaceutical monotherapy. Metformin (MET) is the first-line 
drug used in oral therapy for T2DM in diabetics who do not 
respond to dietary and lifestyle changes. The mechanism of 
action of MET is not completely understood, but it primarily 
appears to act by inhibiting gluconeogenesis and thereby 
suppressing hepatic glucose release [3]. If the goals of glycemic 
control are not achieved using MET monotherapy, combination 
therapy involving agents with complementary mechanisms of 
action is the next logical step in the management of T2DM [4]. 
Recently, newer agents such as vildagliptin (VIL) have been used 
in association with MET for the treatment of T2DM. VIL is a 
potent and selective dipeptidyl peptidase-4 inhibitor that 
prevents the rapid degradation of endogenous glucagon-like 
peptide-1 and glucose-dependent insulinotropic peptide. VIL 
reduces hyperglycemia by increasing insulin secretion and 
decreasing the levels of glucagon in diabetic patients [5]. The 
advantages of combined MET and VIL therapy include superior 
efficacy to that of monotherapy, with a reduced risk for 
hypoglycemia and weight gain, as compared with other classes of 
oral antihyperglycemic agents [6, 7].  
Some analytical methods have been described in the literature for 
the determination of VIL and MET in tablets; these include infrared 
spectroscopy [8, 9] and ultraviolet spectrophotometry [10]. 
However, none of these could monitor VIL and MET simultaneously, 
because of their low selectivity.  
High-performance liquid chromatography (HPLC) has proved to be 
the most suitable technique for routine analyses due to its high 
sensitivity, reproducibility, and ability to separate compounds from 
a range of different matrices, allowing excellent separation and 
reducing analysis times. Despite these advantages, some of the 
available HPLC methods can only monitor VIL and MET separately 
[11-15] and in other cases, simultaneous determination does not 
include MET-related compounds A (MTA), B (MTB), and C (MTC) 
[16-18], as recommended by The European and United States 
Pharmacopoeias [19, 20]. To improve selectivity, some HPLC 
methods used long wavelengths (263 and 293 nm) but this resulted 
in a loss of sensitivity, because VIL and MET are poor chromophore 
molecules
HPLC-tandem mass spectrometry (MS/MS) has been 
demonstrated to have several benefits over other techniques, such 
as sensitivity and the ability to analyze pharmaceutical drugs in 
complex matrices with high selectivity. HPLC-MS/MS is a 
promising technique with the potential to allow the simultaneous 
quantification of VIL, MET, MTA, MTB, and MTC. The present study 
was devoted to the development and validation of an HPLC-MS/MS 
method for simultaneous quantification of these compounds in 
tablets. The method developed was highly selective and sensitive, 
and was capable of detecting low concentrations of the target 
compounds in tablet matrices. 
 [16, 18]. In other cases, sensitivity was improved by using 
shorter wavelengths (210-220 nm), but the method had poor 
selectivity [17]. None of the currently-available HPLC methods for 
the determination of MET-related compounds has sufficient 
selectivity to monitor MTA, MTB, and MTC in the same run, and only 
two of the methods cited above were fully validated in accordance 
with international regulations [11, 12]. This validation is a key step 
in the process of proving that a method is suitable for its intended 
purpose [21]. 
MATERIALS AND METHODS 
Chemicals and reagents 
The VIL standard (98.0% purity) was obtained from Ontario 
Chemicals (Guelph, ON, Canada). Standards of MET hydrochloride 
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(99.7% purity), MTA (100% purity), MTB (100% purity), and MTC 
(100% purity) were obtained from United States Pharmacopoeia 
(Rockville, MD, USA). Acetonitrile and methanol (HPLC grade) were 
purchased from Tedia (Fairfield, CA, USA) and ultrapure water was 
obtained from a Milli-Q system (Milford, MA, USA). Formic acid 
(98-100% purity) was purchased from Merck (Darmstadt, 
Germany).  
Fixed dose tablets of MET hydrochloride (850 mg; from different 
manufacturers), VIL (50 mg; Galvus®, Novartis Corporation), and 
VIL/MET hydrochloride (50/500, 50/850, and 50/1000 mg; Galvus 
Met®, Novartis Corporation) were obtained from local markets in 
Curitiba, Brazil. 
Standard solutions 
Stock solutions (1 mg/mL) of VIL, MET, MTA, MTB, and MTC were 
prepared in methanol and stored at 4°C. Working standard solutions 
were freshly prepared by direct dilution of these stock solutions in 
acetonitrile/water/formic acid (20:80:0.1 v/v/v).  
Sample preparation 
For VIL and MET quantification, twenty tablets of each fixed dose 
combination (Chemicals and reagents section) were weighed 
separately and powdered. A mass equivalent to 1 mg of VIL and 10, 
17, or 20 mg of MET (according to the tablet dosage) was accurately 
weighed and transferred to a 10 mL volumetric flask. Methanol (5 
mL) was added to the flask and the samples were sonicated for 10 
min. The volume was completed with the same solvent and the 
samples were centrifuged for 10 min at 4000 rpm at room 
temperature (Eppendorf 5810-R, Hamburg, Germany). The 
supernatant was diluted (1:2000 v/v) in acetonitrile/water/formic 
acid (20:80:0.1 v/v).  
For MTA, MTB, and MTC quantification, the samples were prepared 
essentially as described above; however the final dilution was 1:200 
v/v. All samples were filtered through a polyvinylidene fluoride 
(PVDF) syringe filter (13 mm, 0.22 µm, Millipore Millex, Billerica, 
MA, USA) before HPLC-MS/MS analysis.  
HPLC-MS/MS conditions 
These analyses were performed on an Agilent 1200 HPLC system 
(Santa Clara, CA, USA) equipped with a G1312B binary pump, 
G1379B degasser, and G1316B column oven, coupled to an Applied 
Biosystems MDS Sciex API 3200 Triple Quadrupole Mass 
Spectrometer (Foster City, CA, USA) equipped with a syringe pump 
(Havard 22 Dual Model, Harvard Apparatus, Holliston, MA, USA) and 
an electrospray ionization (ESI) source. The HPLC-MS/MS system 
was connected to a CTC Sample Manager (Model 2777, Waters 
Corporation, Milford, MA, USA). Chromatographic separation was 
achieved using an XBridge C8 (150 × 4.6 mm, 5 µm) column maintained 
at 25ºC. The isocratic mobile phase consisted of a mixture of 
acetonitrile/water/formic acid (20:80:0.1 v/v). The flow rate was 800 
µL/min and the injection volume were 20 µL. The MS ESI source 
operated in positive ion mode and analyte quantification was achieved 
using multiple reaction monitoring (MRM). Data acquisition was 
performed with the MS workstation using Analyst 1.4 software (MDS 
Sciex, Concord, Canada). High-purity nitrogen was produced using a 
PEAK Scientific Instruments generator (Chicago, IL, USA). The ion source 
parameters were: curtain gas (CUR) 10 psi; collision-activated 
dissociation (CAD) 6 psi; nebulizer gas (GS1) 45 psi; turbo gas (GS2) 40 
psi; ion spray voltage (IS) 5500V, and temperature 600°C. The ion 
transitions and the individual compound parameters, including 
declustering potential (DP), entrance potential (EP), collision cell 
entrance potential (CEP), collision energy (CE), and cell exit potential 
(CXP) are summarized in Table 1. 
 
Table 1: Compound-dependent parameters and ion transitions 
Analyte [M+H]+ Transition   (m/z) 
(m/z) 






d CXPe (V) 
VIL 303.90 154.1 
97.1 




MET 130.05 60.1 
71.1 




MTA 84.90 68.2 20 5 7.5 20 3 
MTB 116.00 60.1 
57.1 




MTC 155.20 71.1 
85.1 




VIL: vildagliptin; MET: metformin; MTA: MET-related compound A; MTB: MET-related compound B; MTC: MET-related compound C; adeclustering 
potential; bentrance potential; ccollision cell entrance potential; dcollision energy; e
 
cell exit potential  
Validation of the analytical method 
The HPLC-MS/MS method was validated according to the 
International Conference on Harmonization guidelines [21]. The 
parameters evaluated were selectivity, limits of detection and 
quantification, linearity, precision, and accuracy. 
Selectivity 
The selectivity was evaluated for each fixed dose matrix by 
comparing the slopes of two analytical curves. The first analytical 
curve was produced by analysis of a serial dilution of the working 
standard solutions to achieve concentrations of 10, 25, 50, 75, and 
100 ng/mL for VIL; 170, 425, 850, 1275, and 1700 ng/mL for MET; 
and 5, 7.5, 10, 12.5, and 15 ng/mL for MTA, MTB, and MTC.  
The second curve was constructed as follows: Initially, the samples 
were prepared as described in the sample preparation section, 
however, the supernatant was diluted 1:20000 (v/v) in the mobile 
phase. The diluted samples were then spiked with the analytes to 
achieve the same concentrations used to prepare the first curve. 
Both of these curves were prepared in triplicate and Student’s t-test 
was used to compare their slopes. 
Limits of detection and quantification 
The limits of detection (LOD) and quantification (LOQ) were 
estimated from the signal-to-noise ratio. To perform this assay, stock 
solutions were diluted in mobile phase until the smallest detectable 
peaks were observed. The LOD was estimated at a signal-to-noise of 
3:1 and the LOQ was estimated as the peak at a signal-to-noise ratio 
of at least 10:1. 
Linearity 
Seven concentrations of each analyte were analyzed in triplicate 
and calibration curves were produced to confirm that there was 
a linear relationship between concentration and analyte peak 
area.  
To conduct this study, stock solutions were diluted in mobile phase 
to obtain the following concentrations: 5, 10, 25, 50, 75, 100, and 
150 ng/mL VIL; 250, 500, 750, 1000, 1250, 1500, and 2000 ng/mL 
MET; 2.5, 5, 7.5, 10, 12.5, 15, and 25 ng/mL MTA, MTB, and MTC. The 
slope, intercept and regression coefficient (r) was calculated by 
weighted 1/x linear regression for VIL, MTA, MTB and MTC and 1/x² 
for MET.  
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Precision and accuracy 
Precision was evaluated using the intra-day and inter-day 
reproducibility of measurements of three replicate analyses of 
working standard solutions at 25, 50, and 75 ng/mL for VIL; 500, 
750, and 1000 ng/mL for MET; and 5, 12.5, and 25 ng/mL for MTA, 
MTB, and MTC. These measurements were conducted by the same 
analyst over a short period of time. The inter-day precision was 
determined by a second analyst after two consecutive days. The 
precision was expressed as the percentage relative standard 
deviation (RSD%) of these measurements. 
Accuracy was measured in triplicate using the method of addition of 
the standard. To perform this assay, twenty tablets of Galvus Met® 
(50 mg of VIL and 850 mg of MET) were weighed and powdered. A 
mass equivalent to 1 mg of VIL and 17 mg of MET was accurately 
weighed and transferred to a 10 mL volumetric flask. Methanol was 
added to the flask and the samples were sonicated and centrifuged. 
The supernatant was diluted (1:20000 v/v) in 
acetonitrile/water/formic acid (20:80:0.1 v/v) and analyzed. Then, 
the diluted sample was spiked with standard solutions at the same 
concentrations used for the precision assay. The amounts of the 
analytes recovered were calculated by subtracting the levels of the 
analytes detected in the spiked samples from those obtained in the 
original (unspiked) samples. Accuracy was expressed as the 
percentage relative error (RE%) of the amount recovered, compared 
with the standard concentrations.  
RESULTS AND DISCUSSION 
Method development 
The MS and MS/MS conditions were automatically optimized by 
direct infusion of individual working standard solutions of VIL, MET, 
MTA, MTB, and MTC. In the MRM mode, the DP, EP, CEP, CE, and CXP 
parameters were optimized for each analyte and the two most 
intense fragments were selected. For MTA, only one fragment ion 
was monitored (m/z 68.2) because the fragments showed low signal 
intensity after MS/MS optimization. At the end of the MS/MS 
optimization, the positive ion mode was found to be the most 
efficient ionization mechanism for each analyte. The structures of all 
the compounds analyzed are shown in Fig. 1. 
The optimization of the source parameters (CUR, CAD, ISV, GS1, GS2, 
and temperature) was accomplished through flow-injection analysis 
(FIA), which coupled the HPLC with the MS. The pump was operated 
at 200 µL/min using an isocratic system with a mobile phase 





























Fig. 1: Chemical structures of (A) metformin (MET)-related 
compound A, (B) MET-related compound B, (C) MET-related 
compound C, (D) MET, and (E) vildagliptin 
 
To identify the optimum chromatographic conditions, mobile phases 
with several combinations of acetonitrile, methanol, and water were 
tested. Different types of column (C18 and C8), and variations in 
flow rate (400-800 µL/min) and column oven temperature 
(25-40°C) were also compared to achieve the best sensitivity, peak 
shape, and the shortest run times.  
The initial experiments were carried out on a C18 column using 
isocratic mobile phases consisting of acetonitrile/water/formic acid 
(10:90:0.1 v/v/v) or methanol/water/formic acid (10:90:0.1 v/v/v), 
both at flow rates of 400 µL/min. This analysis identified that the 
methanol-containing mobile phase did not result in adequate peak 
shapes for all the compounds and the C18 column did not promote 
efficient retention of MET.  
Thus, acetonitrile was selected as the organic solvent in the mobile 
phase and a C8 column was evaluated as the stationary phase. The 
use of a C8 column improved the MET retention time and an 
excellent peak shape was observed for all the compounds. However, 
extensive run time (10.8 min) was observed for VIL and 
consequently, the proportion of acetonitrile in the mobile phase was 
modified from 10 to 15, 20, and 25%. These experiments showed 
that chromatography was optimized using an isocratic mobile phase 
composed of acetonitrile/water/formic acid (20:80:0.1 v/v/v), 
eluted at 800 µL/min, at a column oven temperature of 25°C. 
Representative chromatograms for analytes are shown in Fig. 2.  
 
 
Fig. 2: High-performance liquid chromatography-tandem mass 
spectrometry chromatograms of metformin (MET), MET-related 
compound A (MTA), MET-related compound B (MTB), MET-
related compound C (MTC), and vildagliptin (VIL)Method 
validation 
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This novel HPLC-MS/MS method offered several advantages over 
other methods described in the literature, especially in terms of 
specificity, sensitivity, speed (3.5 min), and the linear range of 
detection achieved with acceptable accuracy and precision. This 
method was uniquely developed for simultaneous determination of 
VIL, MET, MTA, MTB, and MTC. The new HPLC-MS/MS method was 
also fully validated in accordance with current international 
regulations. Thus ensuring reliable results. 
Selectivity 
As demonstrated in Table 2, the comparison of the regression 
equations of the analytical curves (standard solutions and spiked 
matrix) did not identify any significant differences (Student’s t-test, 
p > 0.05). The developed method was therefore considered to be 
selective. 
LOD and LOQ 
The high sensitivity of the method developed in the present study 
was demonstrated its low LOD, estimated at 0.5 ng/mL for VIL and 
MET and 0.6 ng/mL for MTA, MTB, and MTC. The LOQ was estimated 
at 1.5 ng/mL for VIL, 2.5 ng/mL for MTA, and 2 ng/mL for MET, 
MTB, and MTC. 
Linearity 
The calibration curves for VIL, MET, MTA, MTB, and MTC showed an 
excellent linearity with a correlation coefficient (r) > 0.99. The 
precision (RSD) for each compound was < 10% and the accuracy 
was < 11.6%. The regression equations and correlation coefficients 
were y = 8790x + 2330 (r = 0.9991) for VIL, y = 2000x + 1200000 (r 
= 0.9962) for MET, y = 246x + 255 (r = 0.9942) for MTA, y = 1300x + 
-457 (r = 0.9936) for MTB, and y = 3190x + 2130 (r = 0.9978) for 
MTC. 
Precision and accuracy 
The precision and accuracy data are shown in Table 3. The intra-day 
precision ranged from 0.59-4.98%, whereas the inter-day precision 
ranged from 0.47-4.91%. The level of accuracy was satisfactory, with 
RE ranging from 0.13-4.88%. 
 











Galvus® 0.591 - - - - 
Galvus Met® 50/500 0.483 0.442 0.791 0.512 0.060 
Galvus Met® 50/850 0.323 0.546 0.346 0.192 0.282 
Galvus Met® 50/1000 0.834 0.140 0.754 0.670 0.580 
MET manufacturer A - 0.318 0.475 0.276 0.883 
MET manufacturer B - 0.772 0.347 0.238 0.943 
MET manufacturer C - 0.675 0.258 0.732 0.606 
MET manufacturer D - 0.542 0.234 0.768 0.774 
MET manufacturer E - 0.884 0.187 0.639 0.365 
VIL: vildagliptin; MET: metformin; MTA: MET-related compound A; MTB: MET-related compound B; MTC: MET-related compound C. Data shown 
represent the p values (Student’s t test 95% confidence) for comparison of analytical curves prepared in triplicate. 
 
Table 3: Precision and accuracy of high-performance liquid chromatography-tandem mass spectrometry analyses 
Compound Concentration (ng/mL) Precision Accuracy 




VIL 25 1.59 4.23 4.88 
50 3.71 4.82 3.36 
75 1.13 4.35 2.21 
     
MET 500 4.63 4.39 0.26 
750 0.59 3.91 1.57 
1000 2.86 3.89 0.13 
     
MTA 5 3.90 3.80 3.00 
12.5 4.32 4.67 2.13 
25 2.73 3.73 1.93 
     
MTB 5 4.98 3.79 4.17 
12.5 2.75 4.25 4.73 
25 2.37 2.85 1.87 
     
MTC 5 3.78 3.68 4.07 
12.5 2.07 4.91 3.00 
25 2.84 0.47 4.53 
VIL: vildagliptin; MET: metformin; MTA: MET-related compound A; MTB: MET-related compound B; MTC: MET-related compound C. RSD: relative 
standard deviation, RE: relative error. 
 
Sample analysis 
The new method was successfully applied to real samples containing 
VIL (Galvus® 50 mg), 850 mg MET hydrochloride (from five 
different manufacturers), and VIL associated with MET at different 
doses (Galvus Met® containing VIL/MET at 50/500, 50/850, and 
50/1000 mg). The results are shown in Table 4.  
All of the MET hydrochloride tablets analyzed were compliant with 
the United States Pharmacopoeia (95-105%) [20]. The VIL content 
ranged from 95.2-101.2%. No impurities of MET were detected 
using this highly sensitive method. Based on the results obtained. 
The new method was considered a reliable alternative for quality 
control analyses of tablets containing VIL and MET. 
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Table 4: Drug content determined in commercial formulations using high-performance liquid chromatography-tandem mass 
spectrometry 
Sample  Content (%) 
 VIL MET MTA MTB MTC 
Galvus®  95.2 - - - - 
Galvus Met® 50/500  101.2 102.0 ND ND ND 
Galvus Met® 50/850  96.8 101.7 ND ND ND 
Galvus Met® 50/1000  96.5 98.6 ND ND ND 
MET manufacturer A  - 97.0 ND ND ND 
MET manufacturer B  - 104.1 ND ND ND 
MET manufacturer C  - 98.6 ND ND ND 
MET manufacturer D  - 104.4 ND ND ND 
MET manufacturer E  - 102.8 ND ND ND 
VIL: vildagliptin; MET: metformin; MTA: MET-related compound A; MTB: MET-related compound B; MTC: MET-related compound C. ND: not 
detected; -: not present in the formulation. 
 
CONCLUSION 
A fast and sensitive HPLC-MS/MS method was developed for 
quantitative determination of VIL, MET hydrochloride, and MET-
related compounds A, B, and C in tablets. Data from the validation 
study demonstrated that the new method was selective, linear, 
precise, and accurate. This novel HPLC-MS/MS method was also 
highly sensitive, allowing the detection of MET-related compounds 
at low concentrations. Analysis of real samples demonstrated the 
applicability of the new method. Based on these results, the new 
HPLC-MS/MS method could significantly improve the quality control 
of pharmaceutical preparations containing these drugs and can be 
easily applied to routine analysis. 
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